CG Oncology, Inc Common stock

CG Oncology, Inc Common stock

Yahoo Finance • 12 days ago

Cocrystal Pharma: The Strategic Reset Investors May Be Missing

By Mike Sheikh Cocrystal Pharma (NASDAQ: COCP) may look like another undercapitalized, clinical-stage biotech searching for its niche, and in need of a rescue, but there is more to this story than what meets the eye. Investors glancing at... Full story

Yahoo Finance • last month

Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of CG Oncology, Inc. (NASDAQ: CGON) breached their fiduciary duties to shareholders.... Full story

Yahoo Finance • 2 months ago

CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology

DALLAS, July 27, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced the publication of results from the pivotal Phase 3 BOND-003 Cohort C trial evaluating cretostimogene grenadenorepvec monotherapy in patients with... Full story

Yahoo Finance • 2 months ago

Big Insider Buying Puts These 2 Stocks on the Radar

Every investor is looking for opportunities, but finding promising stocks and deciding when to buy is rarely a simple task. Successful investing often depends on separating temporary market moves from businesses that offer meaningful long-... Full story

Yahoo Finance • 3 months ago

The New War on Cancer: Four Public Companies Helping Lead a Medical Revolution

DENVER, June 25, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Cancer treatment is undergoing one of the most significant transformations in modern medical history. For decades, physicians relied primarily on surgery, radiation, and ch... Full story

Yahoo Finance • 4 months ago

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index shedding 0.7% an PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 4 months ago

Sector Update: Healthcare Stocks Decline Tuesday Afternoon

Healthcare stocks were lower Tuesday afternoon, with the NYSE Healthcare Index shedding 0.6% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 4 months ago

CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients

- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat population was 96.0% at... Full story

Yahoo Finance • 4 months ago

RBC Capital Lifts PT on CG Oncology (CGON), Calls PIVOT-006 a Complex Catalyst

CG Oncology, Inc. (NASDAQ:CGON) is one of the best performing healthcare stocks so far in 2026. RBC Capital lifted the price target on CG Oncology, Inc. (NASDAQ:CGON) to $79 from $73 on April 27, reaffirming an Outperform rating on the sha... Full story

Yahoo Finance • 4 months ago

CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates

Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026 PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC a... Full story

Yahoo Finance • 5 months ago

CG Oncology (CGON) Rallied on Pivotal Clinical Results

Meridian Funds, managed by ArrowMark Partners, released its first-quarter 2026 investor letter for “Meridian Small Cap Growth Fund”. A copy of the letter is available to download here. The US equities market started 2026 with volatility dr... Full story

Yahoo Finance • 6 months ago

As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors?

On February 17, 2026, Acorn Capital Advisors reported selling 225,000 shares of Terns Pharmaceuticals(NASDAQ:TERN), an estimated $5.20 million trade based on quarterly average pricing. What happened According to a filing with the Securit... Full story

Yahoo Finance • 6 months ago

This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know

Kynam Capital Management reduced its position in CG Oncology(NASDAQ:CGON), selling 1,059,375 shares in the fourth quarter for an estimated $43.84 million based on quarterly average pricing, according to a February 17, 2026, SEC filing. Wh... Full story

Yahoo Finance • 6 months ago

H.C. Wainwright Raises its Price Target on CG Oncology, Inc. (CGON) to $80 and Maintains a Buy Rating

CG Oncology, Inc. (NASDAQ:CGON) is among the 10 Fastest Growing NASDAQ Stocks to Buy.H.C. Wainwright Raises its Price Target on CG Oncology, Inc. (CGON) to $80 and Maintains a Buy Rating On February 27, 2026, H.C. Wainwright raised the fi... Full story

Yahoo Finance • 6 months ago

CG Oncology GAAP EPS of -$2.08 beats by $0.09, revenue of $4.04M beats by $1.24M

* CG Oncology press release [https://seekingalpha.com/pr/20417455-cg-oncology-reports-2025-year-end-financial-results-and-provides-business-updates] (CGON [https://seekingalpha.com/symbol/CGON]): FY GAAP EPS of -$2.08 beats by $0.09. *... Full story

Yahoo Finance • 9 months ago

Here are the most and least likely M&A targets in biotech, according to Truist

[M&A - concept waiting for mergers and acquisitions.3D rendering on yellow background.] French biotech (ABVX [https://seekingalpha.com/symbol/ABVX]) has emerged as the most likely acquisition target among biotechs in 2026, significantly o... Full story

Yahoo Finance • 9 months ago

New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer

Cretostimogene demonstrated HG-EFS at 3- 6- and 9-months of 95.7%, 84.6% and 80.4%, respectively, in HR BCG UR Ta/T1 Disease in BOND-003 Cohort P CORE-008 Cohort A Data in HR BCG-Naïve NMIBC demonstrates 88% CR and favorable safety with op... Full story

Yahoo Finance • 10 months ago

CG Oncology Announces New Board Member and Board Transition

- Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors - IRVINE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on d... Full story

Yahoo Finance • 10 months ago

CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates

Initiated rolling Biologics License Application (BLA) submission to U.S. FDA for cretostimogene monotherapy in high-risk (HR) BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)Demonstrated continued best-in-disease durability and... Full story

Yahoo Finance • 10 months ago

Noteworthy Tuesday Option Activity: CGON, DECK, ARQT

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in CG Oncology Inc (Symbol: CGON), where a total of 4,018 contracts have traded so far, representing approximately 401,800 underlying... Full story